vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($30.9M vs $18.7M, roughly 1.7× CytomX Therapeutics, Inc.). Community Healthcare Trust Inc runs the higher net margin — 46.6% vs -0.8%, a 47.4% gap on every dollar of revenue. On growth, Community Healthcare Trust Inc posted the faster year-over-year revenue change (5.6% vs -25.7%). Community Healthcare Trust Inc produced more free cash flow last quarter ($35.9M vs $-15.8M). Over the past eight quarters, Community Healthcare Trust Inc's revenue compounded faster (2.7% CAGR vs -15.9%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CHCT vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.9M | $18.7M |
| Net Profit | $14.4M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | 46.6% | -0.8% |
| Revenue YoY | 5.6% | -25.7% |
| Net Profit YoY | 687.6% | 97.6% |
| EPS (diluted) | $0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.9M | — | ||
| Q3 25 | $31.1M | — | ||
| Q2 25 | $29.1M | $18.7M | ||
| Q1 25 | $30.1M | $50.9M | ||
| Q4 24 | $29.3M | $38.1M | ||
| Q3 24 | $29.6M | $33.4M | ||
| Q2 24 | $27.5M | $25.1M | ||
| Q1 24 | $29.3M | $41.5M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $-12.6M | $-154.0K | ||
| Q1 25 | $1.6M | $23.5M | ||
| Q4 24 | $1.8M | $18.9M | ||
| Q3 24 | $1.7M | $5.7M | ||
| Q2 24 | $-10.4M | $-6.5M | ||
| Q1 24 | $3.7M | $13.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | — | -33.7% | ||
| Q1 24 | — | 28.1% |
| Q4 25 | 46.6% | — | ||
| Q3 25 | 5.3% | — | ||
| Q2 25 | -43.2% | -0.8% | ||
| Q1 25 | 5.3% | 46.2% | ||
| Q4 24 | 6.3% | 49.6% | ||
| Q3 24 | 5.9% | 17.2% | ||
| Q2 24 | -37.9% | -26.0% | ||
| Q1 24 | 12.5% | 33.3% |
| Q4 25 | $0.52 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.50 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $0.04 | — | ||
| Q3 24 | $0.04 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $49.0M |
| Total DebtLower is stronger | $532.2M | — |
| Stockholders' EquityBook value | $429.4M | $119.9M |
| Total Assets | $990.8M | $175.1M |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3M | — | ||
| Q3 25 | $3.4M | — | ||
| Q2 25 | $4.9M | $49.0M | ||
| Q1 25 | $2.3M | $47.6M | ||
| Q4 24 | $4.4M | $38.1M | ||
| Q3 24 | $2.8M | $40.6M | ||
| Q2 24 | $734.0K | $43.2M | ||
| Q1 24 | $3.8M | $36.2M |
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | — | ||
| Q2 24 | $457.6M | — | ||
| Q1 24 | $442.3M | — |
| Q4 25 | $429.4M | — | ||
| Q3 25 | $426.8M | — | ||
| Q2 25 | $437.8M | $119.9M | ||
| Q1 25 | $461.3M | $25.0M | ||
| Q4 24 | $476.0M | $-456.0K | ||
| Q3 24 | $477.2M | $-23.5M | ||
| Q2 24 | $497.8M | $-31.2M | ||
| Q1 24 | $511.6M | $-31.7M |
| Q4 25 | $990.8M | — | ||
| Q3 25 | $987.3M | — | ||
| Q2 25 | $966.3M | $175.1M | ||
| Q1 25 | $985.1M | $98.5M | ||
| Q4 24 | $992.6M | $120.5M | ||
| Q3 24 | $981.8M | $139.0M | ||
| Q2 24 | $983.2M | $159.2M | ||
| Q1 24 | $982.7M | $184.7M |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 0.92× | — | ||
| Q1 24 | 0.86× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $56.4M | $-15.8M |
| Free Cash FlowOCF − Capex | $35.9M | $-15.8M |
| FCF MarginFCF / Revenue | 116.0% | -84.6% |
| Capex IntensityCapex / Revenue | 66.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 3.91× | — |
| TTM Free Cash FlowTrailing 4 quarters | $62.8M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.4M | — | ||
| Q3 25 | $12.7M | — | ||
| Q2 25 | $13.8M | $-15.8M | ||
| Q1 25 | $14.4M | $-21.0M | ||
| Q4 24 | $58.9M | $-19.9M | ||
| Q3 24 | $13.8M | $-20.7M | ||
| Q2 24 | $16.7M | $-19.5M | ||
| Q1 24 | $12.6M | $-26.0M |
| Q4 25 | $35.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $9.6M | $-15.8M | ||
| Q1 25 | $9.7M | $-21.2M | ||
| Q4 24 | $34.2M | $-20.0M | ||
| Q3 24 | $6.7M | $-20.7M | ||
| Q2 24 | $9.5M | $-19.6M | ||
| Q1 24 | $7.5M | $-26.2M |
| Q4 25 | 116.0% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 32.9% | -84.6% | ||
| Q1 25 | 32.3% | -41.6% | ||
| Q4 24 | 116.9% | -52.5% | ||
| Q3 24 | 22.5% | -62.1% | ||
| Q2 24 | 34.7% | -78.2% | ||
| Q1 24 | 25.7% | -63.1% |
| Q4 25 | 66.3% | — | ||
| Q3 25 | 16.3% | — | ||
| Q2 25 | 14.5% | 0.1% | ||
| Q1 25 | 15.6% | 0.2% | ||
| Q4 24 | 84.1% | 0.2% | ||
| Q3 24 | 24.2% | 0.1% | ||
| Q2 24 | 26.1% | 0.4% | ||
| Q1 24 | 17.4% | 0.3% |
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | -0.89× | ||
| Q4 24 | 32.14× | -1.05× | ||
| Q3 24 | 7.92× | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.45× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
